

Advances in Hypertrophic Cardiomyopathy

TUESDAY, JUNE 8, 2021



Heart House
Roundtables



Heart House Roundtables

The Heart House Roundtables explore the practical issues that clinicians and patients face every day within high-value clinical areas. They gather a diverse group of experts representing a wide variety of professional societies relevant to a specific topic, as well as other key stakeholders such as patients, federal agencies, health plans, integrated health systems and others as identified. The diversity of expertise is critical to the success of the roundtables, which provide a valuable forum for interactive and facilitated discussions aimed at brainstorming practical solutions to help drive treatment decisions based on the latest evidence and expert opinion. These meetings are designed to optimize in-depth discussion among participants that not only identify and clarify the issues, but also allows participants the opportunity to brainstorm possible solutions to address those issues.

For more information, visit [ACC.org/HeartHouseRoundtables](https://www.acc.org/HeartHouseRoundtables).

Advances in Hypertrophic Cardiomyopathy Roundtable

Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiovascular diseases, both in the US and globally. It is estimated that 1 in 500 have HCM. However, HCM is an underdiagnosed condition with a significant disease burden faced by patients.

The Advances in Hypertrophic Cardiomyopathy Roundtable will address critical issues that continue to challenge the ability of clinicians to provide optimal care for patients with HCM. The goal of this Roundtable is to address the practical issues and key clinical questions facing clinicians in managing and treating HCM. Participants will consider the roles of interdisciplinary and intersystem treatment; standard and novel therapeutics; and opportunities in population health. We aim to identify and address opportunities and challenges in the delivery of guideline-directed care, as well as to define forward looking patient-focused innovations.

Interactive discussions will be used to inform the development of actionable content to be used at the point of care, which may include clinical policy, health policy statements and/or other clinician and patient tools necessary to transform care and improve heart health.

Accelerate Innovation for Medical Excellence in Hypertrophic Cardiomyopathy (AIME HCM)

AIME HCM



Accelerate Innovation for Medical Excellence in Hypertrophic Cardiomyopathy (AIME HCM) is a comprehensive strategy for increasing the awareness and understanding of HCM, activate clinicians, and optimizing disease management to improve patient outcomes.

Through a multi-year, phased approach, the purpose of this effort will be to increase and amplify education, clinical guidance, and practical tools and solutions to support clinicians in identifying and appropriately managing HCM to reduce the burden of the disease and progression.

For more information, visit [ACC.org/HCM](https://www.acc.org/HCM).

ADVANCES IN HYPERTROPHIC CARDIOMYOPATHY

AGENDA Tuesday, June 8, 2021

11:00 a.m.	WELCOME <i>Dipti Itchhaporia, MD, FACC, FAHA, FESC; ACC President</i>
11:05 a.m.	Overview of Roundtable and Introductions <i>Olivia N. Gilbert, MD, MSc, FACC and Daniel Jacoby, MD; Roundtable Chair and Vice-Chair</i>
11:20 a.m.	SESSION 1: CURRENT STANDARDS AND FRONTIERS <ul style="list-style-type: none"> • Session Introduction <i>Olivia N. Gilbert, MD, MSc, FACC and Daniel Jacoby, MD</i> • Multimodality Diagnostics <i>Sharlene M. Day, MD</i> • Standards and Novel Therapies: Thresholds and Interplay <i>Sara Saberi, MD, MS</i> • nHCM and HFpEF Overlap: An Opportunity or a Trap? <i>Ahmad Masri, MD, MS, FACC</i> • Interactive Breakout Session (45 minutes) • Report Back to Full Group (30 minutes)
1:05 p.m.	BREAK
1:20 p.m.	SESSION 2: POPULATION HEALTH- CREATING THOUGHTFUL AND EFFICIENT PATHWAYS FOR SUCCESS <ul style="list-style-type: none"> • Session Introduction <i>Olivia N. Gilbert, MD, MSc, FACC and Daniel Jacoby, MD</i> • Current Status of Access and Outcomes in HCM <i>Daniel Jacoby, MD</i> • Meeting the Value Imperative in Cardiovascular Medicine: Opportunities in Hypertrophic Cardiomyopathy <i>Nihar R. Desai, MD, MPH, FACC</i> • HCM at the Intersection of Sex and Race <i>Neal K. Lakdawala, MD, MSc</i> • Interactive Breakout Session (45 minutes) • Report Back to Full Group (30 minutes)
3:05 p.m.	Q&A AND RECAP SESSION
	Address Questions from WebEx Chat and Prioritize Next Steps <i>Olivia N. Gilbert, MD, MSc, FACC and Daniel Jacoby, MD</i>
3:30 p.m.	ADJOURN

On behalf of the ACC, we are thankful to the members of the Advances in Hypertrophic Cardiomyopathy Roundtable Planning Committee for their hard work and guidance in planning and executing this virtual Roundtable.

ACC ADVANCES IN HYPERTROPHIC CARDIOMYOPATHY ROUNDTABLE PLANNING COMMITTEE



Olivia N. Gilbert, MD, MSc, FACC (Chair)

Assistant Professor, Section on
Cardiovascular Medicine
Wake Forest School of Medicine
Wake Forest Baptist Health
Atrium Health



Daniel Jacoby, MD (Vice-Chair)

Associate Professor of Internal Medicine
Clinical Director of Innovation,
Yale New Haven Health
Director, Cardiomyopathy Program
Yale School of Medicine



Mahesh A. Chandrasekhar, MD

Wake Forest School of Medicine



Martin S. Maron, MD

Director, Hypertrophic Cardiomyopathy
Center and Research Institute
Tufts Medical Center
Director, Chanin T. Mast HCM Center
Morristown Medical Center



Sharlene M. Day, MD

Associate Professor of Medicine and Genetics
Director, Translational Research,
Division of Cardiovascular Medicine
and Cardiovascular Institute
Penn Center for Inherited Cardiovascular Diseases
University of Pennsylvania Perelman School
of Medicine



Steve R. Ommen, MD, FACC

Professor of Medicine, Cardiology
Medical Director, Mayo Hypertrophic
Cardiomyopathy Clinic
Mayo Clinic



Meghan E. Emig, MPAS, PA-C

Assistant Vice President, Cardiovascular Programs
Director of Advanced Practice
Sanger Heart & Vascular Institute

We are grateful to our supporter for their commitment to the
Advances in Hypertrophic Cardiomyopathy Roundtable.

